You are here: Home » News-ANI » Business
Business Standard

Datar Cancer Genetics launches breakthrough blood test for early detection of 15 cancers

ANI  |  Mumbai [India] 

Early detection of has been the Holy Grail for scientists all over the world. Late stage detection is one of the primary reasons for death in patients.

Datar Genetics has developed a simple non-invasive blood test to detect the presence of in seemingly healthy persons, using advanced molecular analysis of particles released by cells. The pattern of various genes expressed in the cells is captured in these particles known as 'exosomes'.

This breakthrough technology has been developed in using latest Artificial Intelligence techniques and is based upon the study of more than 3000 samples from patients. The test analyzes all 22000 protein-coding genes in the human genome and is able to detect the presence of breast, cervices, ovary, endometrium, lung, colon, sarcoma and many more cancers with an accuracy of better than 95 percent.

The test is available in all cities in and the company has made arrangements for collection of the blood sample from home/office. The test can be availed by any person above the age of 35 and who has no previous known history of having any


D. Akolkar, Director of Research and Innovation said that it is a proud moment not only for the company but also for the country as the test has given a pole vault position in research. He also said that the company, working with a frugal budget has beaten the worldwide competition which is funded with billions of dollars and government support. Dr. Akolkar said that research in is an imperative of recent times and Datar Genetics has committed significant resources not only for early detection of but towards making the treatment of stage IV patients more effective and possibly curative.

Datar Genetics Limited has been accredited by NABL and TUV for ISO 9001:2008 for medical reporting and has a modern, differential pressure molecular oncology facility in Nasik, With the launch of the Early Warning Test, the company has entered into a USD 20 billion market worldwide.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Fri, October 13 2017. 11:48 IST